A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess
the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.